- Laureate To Manufacture Alopexx's Product Candidate -
PRINCETON, N.J., April 10, 2008 /PRNewswire/ -- Laureate Pharma, Inc.,
a full-service biopharmaceutical development and protein production
company, today announced that it has entered into a cGMP contract
manufacturing agreement with Alopexx Pharmaceuticals, LLC. According to the
agreement, Laureate will produce Alopexx's mAb F598 antibody under cGMP
conditions. This antibody is planned for use in clinical trials, and later
for commercial production for the treatment and prevention of
Staphylococcus aureus infections. Terms of the manufacturing agreement were
not disclosed.
(Logo: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO )
"We are pleased that Alopexx chose Laureate Pharma as their
manufacturing partner," said Robert J. Broeze, Ph. D., President & CEO of
Laureate. "We will closely collaborate with the Alopexx team and help them
drive their product from development into the clinic."
"Laureate Pharma has a track record of demonstrated expertise in
biopharmaceutical manufacturing, including capabilities in both clinical
and commercial-grade materials," said Dr. Daniel Vlock, President and CEO
of Alopexx. "We look forward to our partnership with Laureate and advancing
our antibody therapeutics program into the clinic."
About Laureate Pharma, Inc.
Laureate Pharma is a full-service biopharmaceutical development and
protein production company located in Princeton, New Jersey. Laureate
Pharma offers superior bioprocessing services that accelerate new products
from development through production. Laureate provides a wide range of
specialized services from process design and development to full-scale cGMP
production, purification, aseptic filling, testing, validation, analytical
services, and regulatory support. Laureate is focused on two active
segments of the biopharmaceutical industry: monoclonal antibodies and
recombinant protein products. Laureate Pharma, Inc. is a wholly owned
subsidiary of Safeguard Scientifics, Inc. (NYSE: SFE) (http://www.safeguard.com).
For more information, contact Michael Cavanaugh, Vice President Sales,
Marketing, and Business Development at (609) 919-3400, or
info@laureatepharma.com or visit http://www.laureatepharma.com .
About Alopexx Pharmaceuticals, LLC
Alopexx Pharmaceuticals was founded to develop a promising new
treatment for serious Staphylococcus aureus infections, including those
caused by methicillin-resistant strains known as MRSA. In the past decade
MRSA has emerged as a major public health problem. Due to the increasing
volume of antimicrobial usage around the world, MRSA and many bacteria have
become increasingly resistant to most commonly used antibiotics. mAb F598
is a fully human monoclonal antibody that has the potential to serve as an
alternative to antibiotics in the fight against MRSA and other S. aureus
infections. Unlike antibiotics, monoclonal antibodies will not lead to the
development of bacterial resistance. The target of the antibody is a
carbohydrate on the bacterial capsule known as PNAG. PNAG has been found to
be a critical factor in the virulence and immune response to MRSA as well
as non-MRSA staphylococcal infections and is also expressed by other
bacterial pathogens. Alopexx Pharmaceuticals, LLC was co-founded by Gerald
Pier, PhD and Daniel Vlock, MD. Its aim is to develop and explore the use
of novel therapies for the treatment and prevention of MRSA and other
serious infections. For more information contact Daniel Vlock, MD at
617-780-1598 or daniel.vlock@alopexx.com or visit http://www.alopexx.com .
SOURCE Laureate Pharma, Inc.
 back to top
Related links:
http://www.laureatepharma.com
http://www.alopexx.com http://www.safeguard.com
Photo Notes:
NewsCom: http://www.newscom.com/cgi-bin/prnh/20080131/NETH020LOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, photodesk@prnewswire.com
CONTACT:
Michael Cavanaugh, Vice President Sales,
Marketing, and Business Development of Laureate Pharma, Inc.,
+1-609-919-3400, or info@laureatepharma.com; Daniel Vlock, MD of
Alopexx Pharmaceuticals, LLC, +1-617-780-1598,
daniel.vlock@alopexx.com
|
